Navigation Links
The First Dedicated Breast Cancer Cell Line Transfection Reagent
Date:4/3/2013

MADISON, Wis., April 3, 2013 /PRNewswire/ -- Mirus Bio has expanded its transfection expertise with the development of the TransIT-BrCa Transfection Reagent a high performance, low toxicity, DNA transfection reagent specifically formulated for breast cancer cell types. This new reagent offers users:

  • Superior DNA Delivery—Achieve high expression levels in breast cancer cell types including: MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, T47D.
  • Formulated for Low Cellular Toxicity—Maintain cell density and reduce experimental biases due to toxicity.
  • Scientifically Proven—Developed by Mirus Bio scientists with nearly 2 decades of gene delivery expertise.

(Logo: http://photos.prnewswire.com/prnh/20100818/CG52502LOGO)

Mirus Bio is dedicated to advancing breast cancer research. In addition to providing scientists with state-of-the-art transfection reagents Mirus will donate a portion of every sale of TransIT-BrCa Transfection Reagent to the Breast Cancer Research Foundation.

Visit www.mirusbio.com for all your transfection needs including data, protocols, technical support or to place an order.

About Mirus Bio LLC –

ONE FOCUS: TRANSFECTION
Every transfection product offered by Mirus Bio is the result of scientific discovery and development from an in-house team of organic chemists, molecular biologists, cell biologists and biochemists. Almost two decades after its founding, transfection continues to be the focal point and passion of Mirus, giving researchers the most reliable products and expertise.


'/>"/>
SOURCE Mirus Bio LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
2. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
3. First Time in Philadelphia Is a Success for Pittcon 2013 (Summary Report)
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. Medifirst Solutions, Inc. Announces Further Update To Shareholders
6. BioMed Realty Trust Declares First Quarter 2013 Common Stock Dividend
7. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
8. First-To-File Patent Law Is Now In Effect, But What Does it Mean?
9. First Southeast Venture Philanthropy Summit Set In NC
10. Rigaku Raman Unveils Upgraded FirstGuard Handheld Analyzer with Industry’s Only 1064nm Wavelength Capabilities
11. First 3D Heads-Up Cataract Surgery Performed in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Research and Markets has ... report to their offering. ... The Global Market for Bioproducts ... 2016 at a CAGR of 8.9%, This ... bioproducts into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
Breaking Biology Technology:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
Breaking Biology News(10 mins):